{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:37:17Z","timestamp":1789983437451,"version":"4.0.1"},"reference-count":53,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2020.0159","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T14:28:46Z","timestamp":1582813726000},"source":"Crossref","is-referenced-by-count":35,"title":["Amyloidosis\u2014the Diagnosis and Treatment of an Underdiagnosed Disease"],"prefix":"10.3238","author":[{"given":"Sandra","family":"Ihne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Morbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Geier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"St\u00f6rk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2020,3,6]]},"reference":[{"key":"10.3238\/arztebl.2020.0159_ref1","doi-asserted-by":"crossref","unstructured":"Palladini G, Merlini G: What is new in diagnosis and management of light chain amyloidosis? Blood 2016; 128: 159\u201368","DOI":"10.1182\/blood-2016-01-629790"},{"key":"10.3238\/arztebl.2020.0159_ref2","doi-asserted-by":"crossref","unstructured":"Gillmore JD, Damy T, Fontana M, et al.: A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 2018; 39: 2799\u2013806","DOI":"10.1093\/eurheartj\/ehx589"},{"key":"10.3238\/arztebl.2020.0159_ref3","doi-asserted-by":"crossref","unstructured":"Gertz MA: Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. Blood Cancer J 2018; 8: 44","DOI":"10.1038\/s41408-018-0080-9"},{"key":"10.3238\/arztebl.2020.0159_ref4","doi-asserted-by":"crossref","unstructured":"Merlini G, Dispenzieri A, Sanchorawala V, et al.: Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers 2018; 4: 38","DOI":"10.1038\/s41572-018-0034-3"},{"key":"10.3238\/arztebl.2020.0159_ref5","doi-asserted-by":"crossref","unstructured":"Schmidt HH, Waddington-Cruz M, Botteman MF, et al.: Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve 2018; 57: 829\u201337","DOI":"10.1002\/mus.26034"},{"key":"10.3238\/arztebl.2020.0159_ref6","doi-asserted-by":"crossref","unstructured":"Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, et al.: Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015; 36: 2585\u201394","DOI":"10.1093\/eurheartj\/ehv338"},{"key":"10.3238\/arztebl.2020.0159_ref7","doi-asserted-by":"crossref","unstructured":"Tanskanen M, Peuralinna T, Polvikoski T, et al.: Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med 2008; 40: 232\u20139","DOI":"10.1080\/07853890701842988"},{"key":"10.3238\/arztebl.2020.0159_ref8","doi-asserted-by":"crossref","unstructured":"Benson MD, Buxbaum JN, Eisenberg DS, et al.: Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid 2018; 25: 215\u20139","DOI":"10.1080\/13506129.2018.1549825"},{"key":"10.3238\/arztebl.2020.0159_ref9","doi-asserted-by":"crossref","unstructured":"Sekijima Y: Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry 2015; 86: 1036\u201343","DOI":"10.1136\/jnnp-2014-308724"},{"key":"10.3238\/arztebl.2020.0159_ref10","doi-asserted-by":"crossref","unstructured":"Ihne S, Morbach C, Obici L, Palladini G, Stork S: Amyloidosis in heart failure. Curr Heart Fail Rep 2019; 16: 285\u2013303","DOI":"10.1007\/s11897-019-00446-x"},{"key":"10.3238\/arztebl.2020.0159_ref11","doi-asserted-by":"crossref","unstructured":"Sekijima Y, Wiseman RL, Matteson J, et al.: The biological and chemical basis for tissue-selective amyloid disease. Cell 2005; 121: 73\u201385","DOI":"10.1016\/j.cell.2005.01.018"},{"key":"10.3238\/arztebl.2020.0159_ref12","doi-asserted-by":"crossref","unstructured":"Liepnieks JJ, Zhang LQ, Benson MD: Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology 2010; 75: 324\u20137","DOI":"10.1212\/WNL.0b013e3181ea15d4"},{"key":"10.3238\/arztebl.2020.0159_ref13","doi-asserted-by":"crossref","unstructured":"Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G: Light chain amyloidosis: Patient experience survey from the amyloidosis research consortium. Adv Ther 2015; 32: 920\u20138","DOI":"10.1007\/s12325-015-0250-0"},{"key":"10.3238\/arztebl.2020.0159_ref14","doi-asserted-by":"crossref","unstructured":"Lane T, Fontana M, Martinez-Naharro A, et al.: Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation 2019; 140: 16\u201326","DOI":"10.1161\/CIRCULATIONAHA.118.038169"},{"key":"10.3238\/arztebl.2020.0159_ref15","doi-asserted-by":"crossref","unstructured":"Grogan M, Scott CG, Kyle RA, et al.: Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 2016; 68: 1014\u201320","DOI":"10.1016\/j.jacc.2016.06.033"},{"key":"10.3238\/arztebl.2020.0159_ref16","doi-asserted-by":"crossref","unstructured":"Coelho T, Maurer MS, Suhr OB: THAOS \u2013 The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin 2013; 29: 63\u201376","DOI":"10.1185\/03007995.2012.754348"},{"key":"10.3238\/arztebl.2020.0159_ref17","doi-asserted-by":"crossref","unstructured":"Quarta CC, Gonzalez-Lopez E, Gilbertson JA, et al.: Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J 2017; 38: 1905\u20138","DOI":"10.1093\/eurheartj\/ehx047"},{"key":"10.3238\/arztebl.2020.0159_ref18","doi-asserted-by":"crossref","unstructured":"Foli A, Palladini G, Caporali R, et al.: The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients. Amyloid 2011; 18 (Suppl 1): 80\u20132","DOI":"10.3109\/13506129.2011.574354029"},{"key":"10.3238\/arztebl.2020.0159_ref19","doi-asserted-by":"crossref","unstructured":"Gillmore JD, Maurer MS, Falk RH, et al.: Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016; 133: 2404\u201312","DOI":"10.1161\/CIRCULATIONAHA.116.021612"},{"key":"10.3238\/arztebl.2020.0159_ref20","doi-asserted-by":"crossref","unstructured":"Bochtler T, Hegenbart U, Kunz C, et al.: Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol 2015; 33: 1371\u20138","DOI":"10.1200\/JCO.2014.57.4947"},{"key":"10.3238\/arztebl.2020.0159_ref21","doi-asserted-by":"crossref","unstructured":"Bochtler T, Hegenbart U, Kunz C, et al.: Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. Blood 2016; 128: 594\u2013602","DOI":"10.1182\/blood-2015-10-676361"},{"key":"10.3238\/arztebl.2020.0159_ref22","doi-asserted-by":"crossref","unstructured":"Bochtler T, Hegenbart U, Kunz C, et al.: Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan\/dexamethasone. Amyloid 2014; 21: 9\u201317","DOI":"10.3109\/13506129.2013.854766"},{"key":"10.3238\/arztebl.2020.0159_ref23","doi-asserted-by":"crossref","unstructured":"Sanchorawala V, Palladini G, Kukreti V, et al.: A phase 1\/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood 2017; 130: 597\u2013605","DOI":"10.1182\/blood-2017-03-771220"},{"key":"10.3238\/arztebl.2020.0159_ref24","doi-asserted-by":"crossref","unstructured":"Muchtar E, Dispenzieri A, Leung N, et al.: Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia 2018; 32: 2240\u20139","DOI":"10.1038\/s41375-018-0060-x"},{"key":"10.3238\/arztebl.2020.0159_ref25","doi-asserted-by":"crossref","unstructured":"Ericzon BG, Wilczek HE, Larsson M, et al.: Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation 2015; 99: 1847\u201354","DOI":"10.1097\/TP.0000000000000574"},{"key":"10.3238\/arztebl.2020.0159_ref26","doi-asserted-by":"crossref","unstructured":"Muchtar E, Grogan M, Dasari S, Kurtin PJ, Gertz MA: Acquired transthyretin amyloidosis after domino liver transplant: phenotypic correlation, implication of liver retransplantation. J Neurol Sci 2017; 379: 192\u20137","DOI":"10.1016\/j.jns.2017.06.013"},{"key":"10.3238\/arztebl.2020.0159_ref27","doi-asserted-by":"crossref","unstructured":"Adams D, Gonzalez-Duarte A, O\u2018Riordan WD, et al.: Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11\u201321","DOI":"10.1056\/NEJMoa1716153"},{"key":"10.3238\/arztebl.2020.0159_ref28","doi-asserted-by":"crossref","unstructured":"Solomon SD, Adams D, Kristen A, et al.: Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 2019; 139: 431\u201343","DOI":"10.1161\/CIRCULATIONAHA.118.035831"},{"key":"10.3238\/arztebl.2020.0159_ref29","doi-asserted-by":"crossref","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, et al.: Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 22\u201331","DOI":"10.1056\/NEJMoa1716793"},{"key":"10.3238\/arztebl.2020.0159_ref30","doi-asserted-by":"crossref","unstructured":"Bulawa CE, Connelly S, Devit M, et al.: Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA 2012; 109: 9629\u201334","DOI":"10.1073\/pnas.1121005109"},{"key":"10.3238\/arztebl.2020.0159_ref31","doi-asserted-by":"crossref","unstructured":"Sekijima Y, Dendle MA, Kelly JW: Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 2006; 13: 236\u201349","DOI":"10.1080\/13506120600960882"},{"key":"10.3238\/arztebl.2020.0159_ref32","doi-asserted-by":"crossref","unstructured":"Penchala SC, Connelly S, Wang Y, et al.: AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci USA 2013; 110: 9992\u20137","DOI":"10.1073\/pnas.1300761110"},{"key":"10.3238\/arztebl.2020.0159_ref33","doi-asserted-by":"crossref","unstructured":"Sant\u2018Anna R, Gallego P, Robinson LZ, et al.: Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nat Commun 2016; 7: 10787","DOI":"10.1038\/ncomms10787"},{"key":"10.3238\/arztebl.2020.0159_ref34","doi-asserted-by":"crossref","unstructured":"Coelho T, Maia LF, da Silva AM, et al.: Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 2013; 260: 2802\u201314","DOI":"10.1007\/s00415-013-7051-7"},{"key":"10.3238\/arztebl.2020.0159_ref35","doi-asserted-by":"crossref","unstructured":"Coelho T, Maia LF, Martins da Silva A, et al.: Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012; 79: 785\u201392","DOI":"10.1212\/WNL.0b013e3182661eb1"},{"key":"10.3238\/arztebl.2020.0159_ref36","doi-asserted-by":"crossref","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al.: Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018; 379: 1007\u201316","DOI":"10.1056\/NEJMoa1805689"},{"key":"10.3238\/arztebl.2020.0159_ref37","doi-asserted-by":"crossref","unstructured":"Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva MJ: Synergy of combined doxycycline\/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med 2010; 8: 74","DOI":"10.1186\/1479-5876-8-74"},{"key":"10.3238\/arztebl.2020.0159_ref38","doi-asserted-by":"crossref","unstructured":"Higaki JN, Chakrabartty A, Galant NJ, et al.: Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin. Amyloid 2016; 23: 86\u201397","DOI":"10.3109\/13506129.2016.1148025"},{"key":"10.3238\/arztebl.2020.0159_ref39","doi-asserted-by":"crossref","unstructured":"Comenzo RL, Reece D, Palladini G, et al.: Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 2012; 26: 2317\u201325","DOI":"10.1038\/leu.2012.100"},{"key":"10.3238\/arztebl.2020.0159_ref40","doi-asserted-by":"crossref","unstructured":"Milani P, Basset M, Russo F, Foli A, Merlini G, Palladini G: Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. Blood 2017; 130: 625\u201331","DOI":"10.1182\/blood-2017-02-767467"},{"key":"10.3238\/arztebl.2020.0159_ref41","doi-asserted-by":"crossref","unstructured":"Conceicao I, Coelho T, Rapezzi C, et al.: Assessment of patients with hereditary transthyretin amyloidosis \u2013 understanding the impact of management and disease progression. Amyloid 2019; 26: 103\u201311","DOI":"10.1080\/13506129.2019.1627312"},{"key":"10.3238\/arztebl.2020.0159_ref42","doi-asserted-by":"crossref","unstructured":"Conceicao I, Damy T, Romero M, et al.: Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. Amyloid 2019; 26: 3\u20139","DOI":"10.1080\/13506129.2018.1556156"},{"key":"10.3238\/arztebl.2020.0159_ref43","doi-asserted-by":"crossref","unstructured":"Gertz MA, Skinner M, Connors LH, Falk RH, Cohen AS, Kyle RA: Selective binding of nifedipine to amyloid fibrils. Am J Cardiol 1985; 55: 1646","DOI":"10.1016\/0002-9149(85)90996-8"},{"key":"10.3238\/arztebl.2020.0159_ref44","doi-asserted-by":"crossref","unstructured":"Pollak A, Falk RH: Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest 1993; 104: 618\u201320","DOI":"10.1378\/chest.104.2.618"},{"key":"10.3238\/arztebl.2020.0159_ref45","doi-asserted-by":"crossref","unstructured":"Kristen AV, Dengler TJ, Hegenbart U, et al.: Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 2008; 5: 235\u201340","DOI":"10.1016\/j.hrthm.2007.10.016"},{"key":"10.3238\/arztebl.2020.0159_ref46","doi-asserted-by":"crossref","unstructured":"Gupta V, Lipsitz LA: Orthostatic hypotension in the elderly: diagnosis and treatment. Am J Med 2007; 120: 841\u20137","DOI":"10.1016\/j.amjmed.2007.02.023"},{"key":"10.3238\/arztebl.2020.0159_ref47","doi-asserted-by":"crossref","unstructured":"Berk JL, Suhr OB, Obici L, et al.: Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013; 310: 2658\u201367","DOI":"10.1001\/jama.2013.283815"},{"key":"10.3238\/arztebl.2020.0159_ref48","doi-asserted-by":"crossref","unstructured":"Kristen AV, Lehrke S, Buss S, et al.: Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol 2012; 101: 805\u201313","DOI":"10.1007\/s00392-012-0463-z"},{"key":"10.3238\/arztebl.2020.0159_ref49","doi-asserted-by":"crossref","unstructured":"aus dem Siepen F, Bauer R, Aurich M, et al.: Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study. Drug Des Devel Ther 2015; 9: 6319\u201325","DOI":"10.2147\/DDDT.S96893"},{"key":"10.3238\/arztebl.2020.0159_ref50","doi-asserted-by":"crossref","unstructured":"Cappelli F, Martone R, Taborchi G, et al.: Epigallocatechin-3-gallate tolerability and impact on survival in a cohort of patients with transthyretin-related cardiac amyloidosis. A single-center retrospective study. Intern Emerg Med 2018; 13: 873\u201380","DOI":"10.1007\/s11739-018-1887-x"},{"key":"10.3238\/arztebl.2020.0159_ref51","doi-asserted-by":"crossref","unstructured":"Obici L, Cortese A, Lozza A, et al.: Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid 2012; 19 (Suppl 1): 34\u20136","DOI":"10.3109\/13506129.2012.678508"},{"key":"10.3238\/arztebl.2020.0159_ref52","doi-asserted-by":"crossref","unstructured":"Gamez J, Salvad\u00f3 M, Reig N: Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study. Amyloid 2019; 26: 74\u201384","DOI":"10.1080\/13506129.2019.1597702"},{"key":"10.3238\/arztebl.2020.0159_ref53","doi-asserted-by":"crossref","unstructured":"Judge DP, Heitner SB, Falk RH: Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. J Am Coll Cardiol 2019; 74: 285\u201395","DOI":"10.1016\/j.jacc.2019.03.012"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2020.0159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T09:53:21Z","timestamp":1638784401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2020.0159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,6]]},"references-count":53,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2020.0159","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,6]]}}}